Dr. Chandra Vargeese joined Wave in 2014 as Senior Vice President and Head of Research and was named Chief Technology Officer in 2020. In this role, she is responsible for the advancement of Wave’s PRISM™ platform, which combines best-in-class oligonucleotide chemistry, multiple RNA-targeting modalities, and novel insights from human genetics. PRISM is foundational to all of Wave’s drug discovery and development efforts.
Chandra is one of the industry’s leading oligonucleotide chemists with approximately 30 years of oligonucleotide research experience. She has also authored numerous scientific publications and patents in the field.
Before joining Wave, Chandra worked at Novartis as Executive Director of Chemistry and Delivery, RNA Therapeutics Division for more than five years. Prior to joining Novartis, she led siRNA delivery in the RNA Therapeutics division at Merck & Co. Chandra joined Merck through its $1.1 billion acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before her time at Sirna Therapeutics, she served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen® (pegaptanib), an approved therapy for treating wet AMD.
Chandra earned a PhD in organic chemistry at the Indian Institute of Science, Bangalore, India, and completed post-doctoral work at the University of Rhode Island.
What is Chandra Vargeese's net worth?
The estimated net worth of Chandra Vargeese is at least $2.96 million as of February 9th, 2026. Vargeese owns 408,246 shares of WAVE Life Sciences stock worth more than $2,959,784 as of April 1st. This net worth evaluation does not reflect any other assets that Vargeese may own. Learn More about Chandra Vargeese's net worth.
How do I contact Chandra Vargeese?
Has Chandra Vargeese been buying or selling shares of WAVE Life Sciences?
Chandra Vargeese has not been actively trading shares of WAVE Life Sciences during the last quarter. Most recently, Chandra Vargeese sold 3,228 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a transaction totalling $43,416.60. Following the completion of the sale, the insider now directly owns 408,246 shares of the company's stock, valued at $5,490,908.70. Learn More on Chandra Vargeese's trading history.
Who are WAVE Life Sciences' active insiders?
Are insiders buying or selling shares of WAVE Life Sciences?
In the last twelve months, WAVE Life Sciences insiders bought shares 1 times. They purchased a total of 1,470,000 shares worth more than $27,930,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 1,236,383 shares worth more than $16,853,139.35. The most recent insider tranaction occured on February, 26th when insider Chris Francis sold 33,194 shares worth more than $499,569.70. Insiders at WAVE Life Sciences own 24.0% of the company.
Learn More about insider trades at WAVE Life Sciences. Information on this page was last updated on 2/26/2026.
